Breaking Finance News

Sierra Oncology (FRA:SRRA) has been upgraded from Hold to Buy in a statement by Jefferies earlier today.

Jefferies has upgraded Sierra Oncology (FRA:SRRA) from Hold to Buy in a statement released on 10/23/2017.

Showing a price of 1.64EUR, Sierra Oncology (FRA:SRRA) traded 7.93% higher on the day. The last closing price is up 25.48% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same period. SRRA has recorded a 50-day average of 1.64EUR and a two hundred day average of 1.41EUR. Volume of trade was down over the average, with 191,953 shares of SRRA changing hands under the typical 293,131

Performance Chart

Sierra Oncology (FRA:SRRA)

With a total market value of 0 EUR, Sierra Oncology has with a one year low of 1.10EUR and a one year high of 1.94EUR .

More About Sierra Oncology (FRA:SRRA)

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The companyÂ’s lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.